Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
Godaly G, Carlsson O, Broman M
Clinical kidney journal · 29 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Authors
- At least one author declares a financial tie to industry
Based on full-text disclosure statement.
Publication
- Published
- 2015-12-19 · Clin Kidney J · vol. 9 · issue 2 · pp. 205–210
- Publisher
- Oxford University Press
- Cited
- 36 citations · more than 76% of similar papers · 1.1× the field average
- References
- 34 works
- Access
- Open access (journal) · CC-BY-NC
- Research areas
- Parathyroid Disorders and Treatments · Magnesium in Health and Disease · Dialysis and Renal Disease Management
- Keywords
- Renal replacement therapy, Medicine, Hypophosphatemia, Phosphate, Dialysis, Magnesium, Retrospective cohort study, Urology, Internal medicine, Chemistry, Biochemistry
3 authors
From SE
- Gabriela Godaly · correspondingLund University
- Ola CarlssonLund University
- Marcus BromanSkåne University Hospital
Abstract
Background
Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis.
Methods
We retrospectively analysed 112 patients treated with CRRT at Skåne University Hospital, Sweden. The control group was treated with Hemosol(®) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium(®) (phosphate; n = 76) as dialysis fluid and Hemosol(®) B0 as replacement fluid.
Results
Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid-base parameters were detected between the groups.
Conclusions
In this larger cohort, we could confirm that Phoxilium(®) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.